Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 03 Jan 2025
Structural elements of private equity ownership linked to higher mortality, complication rates
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
Is Laughter Good for Blood Glucose Control?
2.
Lung nodules seen in a high percentage of non-smokers
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Shorter but More Intense RT: A Better Option for HNSCC?
5.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
1.
Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights
2.
A New Dawn for Triple-Negative Breast Cancer: Emerging Therapies and the Art of Healing
3.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
4.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
5.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge